Compelo Medical Devices - Latest industry news and analysis is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

US Cardiovascular Surgeon Survey For Symphony Medical’s Algisyl-LVR

Symphony Medical Inc, announced the results of a survey in which 96 percent of the participating US Cardiovascular surgeons reacted very favorably to the Company’s novel therapy, Algisyl-LVR to treat heart failure (CHF) patients with dilated cardiomyopathy. Methodology: US based Cardiovascular surgeons were contacted via email by an independent party to participate in an internet survey regarding a new CHF technology Surgeons were screened to ensure they had performed a minimum of 150 cardiovascular surgeries in the last 12 months Screened surgeons (n=80) responded to survey questions via an internet link after viewing a presentation of the Symphony technology Executive Summary of Results: US Cardiovascular surgeons were surveyed regarding: Current incidence of Dilated Cardiomyopathy in cardiac surgery patients Reaction to the Algisyl-LVR concept Results reveal that over 20% of all CABG/Valve surgical patients present with Dilated Cardiomyopathy at time of surgery and the majority of surgical patients with Dilated Cardiomyopathy appear to be potential candidates for a concomitant procedure Surgeons reacted very favorably to the Algisyl-LVR concept – 96% said they would try the product Surgeons also believe the product will enable surgery for approximately 33% of patients who are currently disqualified for surgery due to Dilated Cardiomyopathy Surgeons were most intrigued by the potential efficacy and the simplicity of the concept The Company’s novel heart failure therapy, developed in collaboration with clinicians at the University of California, San Francisco and the Henry Ford Health System, Detroit, employs an approach intended to prevent or reverse the progression of congestive heart failure in patients who have an enlarged left ventricle as a result of mitral valve regurgitation, ischemia, dilated cardiomyopathy and/or other disorders.